Clinical Trial: A Phase 3 Trial of MM120 for Major Depressive Disorder (Emerge)

U.S., April 25 -- ClinicalTrials.gov registry received information related to the study (NCT06941844) titled 'A Phase 3 Trial of MM120 for Major Depressive Disorder (Emerge)' on April 16.

Brief Summary: A Phase 3 Double-blind, Placebo-controlled Study (Part A) with an Open-label Extension (Part B) Evaluating MM120 Compared to Placebo in Major Depressive Disorder - Emerge

Study Start Date: April 14

Study Type: INTERVENTIONAL

Condition: Major Depressive Disorder

Intervention: OTHER: Placebo

A substance that is designed to have no therapeutic value

DRUG: MM120 (LSD D-Tartrate)

A psychoactive substance that mediates effects mainly through an agonist activity in the serotonin 2A receptor (5-HT2A)

Recruitment Status: RECRUITING

Sponso...